24/7 Market News Snapshot 01 October, 2025 – Palisade Bio, Inc. Common Stock (NASDAQ:PALI)

October 1, 2025

DENVER, Colo., 01 October, 2025 (www.247marketnews.com) – (Nasdaq:PALI) are discussed in this article.
Palisade Bio, Inc. (Nasdaq:PALI), a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for autoimmune, inflammatory, and fibrotic diseases, has recently attracted significant attention in the financial markets. Following the announcement of an underwritten public offering of 171,440,559 shares of its common stock at a price of $0.70 per share, the stock has seen a notable increase in its market value. Opening at $0.842, PALI shares surged to $1.112, which translates to an impressive gain of 29.35% within a short timeframe. This spike in stock price coincides with the heightened trading volume, reaching 8.12 million shares, reflecting robust investor interest.

The offering is projected to generate gross proceeds of approximately $120 million, prior to deducting underwriting discounts and expenses, thereby strengthening Palisade’s financial position. Ladenburg Thalmann & Co. Inc. serves as the sole book-running manager for the offering, which also includes a 45-day option for underwriters to purchase up to an additional 25,714,285 shares at the public offering price. This indicates considerable confidence in PALI’s growth potential.

The transaction’s closing is expected around October 2, 2025, pending the satisfaction of customary closing conditions. Furthermore, this recent announcement underscores Palisade Bio’s commitment to transparency and adherence to regulatory requirements, particularly following the recent effectiveness of its registration statement.

As the company advances its pipeline of novel therapeutics, the capital raised through this offering will play a crucial role in supporting its mission to provide effective treatment solutions for patients grappling with challenging diseases. Investors are encouraged to monitor PALI’s developments, as its upward momentum and successful capital raising efforts may position the company for continued growth and innovation in the biopharmaceutical sector.

Related news for (PALI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.